Show simple item record

dc.contributor.authorRaymond, Meriel
dc.contributor.authorChing-A-Sue, Gemma
dc.contributor.authorOliver, Van Hecke
dc.date.accessioned2020-05-21T03:46:31Z
dc.date.available2020-05-21T03:46:31Z
dc.date.issued2020-05-18
dc.identifier.urihttps://www.cebm.net/covid-19/mast-cell-stabilisers-leukotriene-antagonists-and-antihistamines-a-rapid-review-of-effectiveness-in-covid-19/en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12663/1569
dc.description.abstractMast cells are present in mucosal and connective tissues throughout the body. They participate in the innate and adaptive immune process and have an important role in inflammation and allergy. Mast cells located in the submucosa of the respiratory tract are known to be activated by the SARS-CoV-2 virus. Once activated, degranulation occurs releasing histamine and proteases. Late mast-cell activation leads to the release of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α. Vitamin D is required to maintain the stability of mast cells, and Vitamin D deficiency results in mast cell activation.en_US
dc.languageEnglishen_US
dc.subjectCOVID-19en_US
dc.subjectCoronavirusen_US
dc.subjectInfectious Diseasesen_US
dc.subjectMast Cellsen_US
dc.subjectLeukotriene Antagonistsen_US
dc.subjectHistamine Antagonistsen_US
dc.titleMast cell stabilisers, leukotriene antagonists and antihistamines: A rapid review of effectiveness in COVID-19en_US
eihealth.countryOthersen_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typePublished Articleen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.relation.ispartofjournalCentre for Evidence-Based Medicineen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record